keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable stent

keyword
https://www.readbyqxmd.com/read/28532901/long-term-surveillance-of-zinc-implant-in-murine-artery-surprisingly-steady-biocorrosion-rate
#1
Adam Drelich, Shan Zhao, Roger J Guillory, Jaroslaw W Drelich, Jeremy Goldman
Metallic zinc implanted into the abdominal aorta of rats out to 6 months has been demonstrated to degrade while avoiding responses commonly associated with the restenosis of vascular implants. However, major questions remain regarding whether a zinc implant would ultimately passivate through the production of stable corrosion products or via a cell mediated fibrous encapsulation process that prevents the diffusion of critical reactants and products at the metal surface. Here, we have conducted clinically relevant long term in vivo studies in order to characterize late stage zinc implant biocorrosion behavior and products to address these critical questions...
May 19, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28523173/thrombotic-responses-to-coronary-stents-bioresorbable-scaffolds-and-the-kounis-hypersensitivity-associated-acute-thrombotic-syndrome
#2
REVIEW
Nicholas G Kounis, Ioanna Koniari, Anastasios Roumeliotis, Grigorios Tsigas, George Soufras, Nicholas Grapsas, Periklis Davlouros, George Hahalis
Percutaneous transluminal coronary angioplasty with coronary stent implantation is a life-saving medical procedure that has become, nowadays, the most frequent performed therapeutic procedure in medicine. Plain balloon angioplasty, bare metal stents, first and second generation drug-eluting stents, bioresorbable and bioabsorbable scaffolds have offered diachronically a great advance against coronary artery disease and have enriched our medical armamentarium. Stented areas constitute vulnerable sites for endothelial damage, endothelial dysfunction, flow turbulence, hemorheologic changes, platelet dysfunction, coagulation changes and fibrinolytic disturbances...
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28516211/early-endothelialization-associated-with-a-biolimus-a9-bioresorbable-polymer-stent-in-a-porcine-coronary-model
#3
Masayuki Mori, Kenji Sakata, Chiaki Nakanishi, Takuya Nakahashi, Masa-Aki Kawashiri, Kazuaki Yoshioka, Yoh Takuwa, Hirofumi Okada, Jun-Ichiro Yokawa, Masaya Shimojima, Tsuyoshi Yoshimuta, Shohei Yoshida, Masakazu Yamagishi, Kenshi Hayashi
Although Nobori(®), with a bioresorbable polymer and biolimus A9 abluminal coating, has unique characteristics, few data exist regarding endothelialization early after implantation. Fifteen Nobori(®) and 14 control bare-metal stents (S-stent™) were implanted in 12 pigs. Histopathology of stented segments, inflammation, and intimal fibrin content was evaluated on the 2nd and 14th day after implantation. On the 2nd day, endothelial cells were morphologically and immunohistologically confirmed on the surface of both stents, although some inflammatory cells might be involved...
May 17, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28512285/coronary-aneurysm-formation-after-bioresorbable-vascular-scaffold-implantation-resulting-in-acute-myocardial-infarction
#4
Ching-Chang Fang, Yeun Tarl Fresner Ng Jao
BACKGROUND Development of a true coronary aneurysm after percutaneous coronary intervention is a rare event, and a coronary aneurysm resulting in acute myocardial infarction is even rarer. Coronary aneurysm formation after bioresorbable vascular scaffold (BVS) implantation, eventually leading to thrombosis, embolization, and myocardial infarction, has never been reported before in the literature. CASE REPORT A 62-year-old man received an elective BVS for a proximal left anterior descending lesion. Two months later, he suffered from a non-ST-segment myocardial infarction...
May 17, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28512069/optical-coherence-tomography-findings-insights-from-the-randomised-multicentre-trial-investigating-angiographic-outcomes-of-hybrid-sirolimus-eluting-stents-with-biodegradable-polymer-compared-with-everolimus-eluting-stents-with-durable-polymer-in-chronic-total
#5
Koen Teeuwen, Eva M Spoormans, Johan Bennett, Christophe Dubois, Walter Desmet, Giovanni J Ughi, Ann Belmans, Johannes C Kelder, Jan G P Tijssen, Pierfrancesco Agostoni, Maarten J Suttorp, Tom Adriaenssens
AIMS: The PRISON IV trial investigated the next-generation sirolimus-eluting stent (SES) with ultra-thin struts and biodegradable polymer against the second-generation everolimus-eluting stent (EES) with thin struts and durable polymer in patients with successfully recanalised chronic total occlusions (CTO). In this study, we examined the secondary optical coherence tomography endpoints. METHODS AND RESULTS: The main PRISON IV trial randomised 330 patients to either SES or EES...
May 18, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504231/poland-coronary-and-structural-heart-interventions-from-2010-to-2015
#6
Jacek Legutko, Zbigniew Siudak, Radosław Parma, Andrzej Ochała, Dariusz Dudek
For the last five years, invasive cardiology in Poland has developed extensively. Currently, 98% of the 161 Polish cathlabs operate in 24/7 mode, 37 of them supported by cardiac surgery departments on-site. A certification curriculum for interventional cardiology operators is supported by dedicated workshops and scientific meetings during national conferences. The rise in the number of coronary angiographies and PCIs was paralleled by an increased use of drug-eluting stents, bioresorbable vascular scaffolds and physiologic assessment of coronary arteries...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28500737/clinical-outcomes-of-overlapping-versus-non-overlapping-everolimus-eluting-absorb-bioresorbable-vascular-scaffolds-an-analysis-from-the-multicentre-prospective-rai-registry-clinicaltrials-gov-identifier-nct02298413
#7
Giuseppe Tarantini, Marco Mojoli, Giulia Masiero, Bernardo Cortese, Bruno Loi, Attilio Varricchio, Gabriele Gabrielli, Alessandro Durante, Giampaolo Pasquetto, Paolo Calabrò, Roberto Gistri, Gabriele Tumminello, Leonardo Misuraca, Francesco Pisano, Alfonso Ielasi, Pietro Mazzarotto, Sebastian Coscarelli, Valerio Lucci, Luciano Moretti, Annamaria Nicolino, Alessandro Colombo, Zoran Olivari, Massimo Fineschi, Davide Piraino, Luigi Piatti, Umberto Canosi, Paola Tellaroli, Donatella Corrado, Chiara Rovera, Giuseppe Steffenino
OBJECTIVES: To compare clinical outcomes of patients treated with overlapping versus non-overlapping Absorb BVS. BACKGROUND: Limited data are available on the clinical impact of stent overlap with the Absorb BVS bioresorbable stent. METHODS: We compared outcomes of patients receiving overlapping or non-overlapping Absorb BVS in the multicenter prospective RAI Registry. RESULTS: Out of 1,505 consecutive patients treated with Absorb BVS, 1,384 were eligible for this analysis...
May 13, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28476635/the-fate-of-incomplete-scaffold-apposition-of-everolimus-eluting-bioresorble-scaffolds-a-serial-optical-coherence-tomography-analysis
#8
Takao Sato, Ralph Tölg, Mohamed El-Mawardy, Dmitriy S Sulimov, Gert Richardt, Mohamed Abdel-Wahab
BACKGROUND: Incomplete stent apposition (ISA) can be divided into acute and late forms. Late ISA may be due to persistent ISA or late-acquired ISA (LAISA). This study evaluated the natural course of ISA after bioresorbable vascular scaffold (BRS) implantation using optical coherence tomography (OCT). METHODS: Thirty-two patients (45 BRS) were assessed immediately after BRS implantation and 1 year thereafter using OCT. Acute ISA identified after BRS implantation but absent at follow-up was defined as resolved; otherwise, it was considered persistent...
May 2, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28471557/insights-from-2d-and-3d-quantitative-angiographic-assessment-of-bioresorbable-everolimus-eluting-vascular-scaffolds
#9
Guy Witberg, Ifat Lavi, Hana Vaknin Assa, Katia Orvin, Abid Assali, Ran Kornowski
BACKGROUND: Bioresorbable vascular scaffold (BVS) is a promising technology that potentially offers several advantages over contemporary coronary drug-eluting stents (DES). Crucial to BVS implantation is the correct choice of scaffold size (diameter and length) in order to avoid "geographic miss" in length, provide the maximal support to the vessel wall, and avoid leaving "free-floating" foreign material in the coronary vasculature. OBJECTIVES: To assess the optimal method for measuring coronary stenosis prior to BVS implantation...
July 2016: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28471086/risk-and-timing-of-clinical-events-according-to-diabetic-status-of-patients-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-stent-2-year-results-from-a-propensity-score-matched-comparison-of-absorb-extend-and-spirit
#10
Carlos M Campos, Adriano Caixeta, Marcelo Franken, Antonio L Bartorelli, Robert J Whitbourn, Chiung-Jen Wu, Hsien Li Paul Kao, Mohd Ali Rosli, Didier Carrie, Bernard De Bruyne, Gregg W Stone, Patrick W Serruys, Alexandre Abizaid
OBJECTIVES: to compare the occurrence of clinical events in diabetics treated with the Absorb bioresorbable vascular scaffold (Absorb BVS; Abbott Vascular, Santa Clara, CA) versus everolimus-eluting metal stents (EES; XIENCE V; Abbott Vascular, Santa Clara, CA) BACKGROUND: There are limited data dedicated to clinical outcomes of diabetic patients treated with bioresorbable scaffolds (BRS) at 2-year horizon. METHODS: The present study included 812 patients in the ABSORB EXTEND study in which a total of 215 diabetic patients were treated with Absorb BVS...
May 4, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28471065/novel-ultrahigh-molecular-weight-amorphous-plla-bioresorbable-coronary-scaffold-upsized-up-to-0-8-mm-beyond-nominal-diameter-an-oct-and-histopathology-study-in-porcine-coronary-artery-model
#11
Pawel Gasior, Yanping Cheng, Edward A Estrada, Jenn McGregor, Kamal Ramzipoor, Chang Lee, Gerard B Conditt, Serge D Rousselle, Juan F Granada, Grzegorz L Kaluza
OBJECTIVES: The aim of the study was to evaluate the biomechanical properties and healing pattern of novel sirolimus-eluting, ultrahigh molecular weight amorphous poly-L-lactic acid bioresorbable scaffolds (S-BRS) that have been postdilated by 0.55 and 0.8 mm beyond the nominal diameters within the pressure-diameter compliance chart range. BACKGROUND: Due to the inherent limitations of bioabsorbable polymeric materials, overexpansion/upsizing may be very limited for some BRS such as the benchmark Absorb BVS...
May 4, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28468954/long-term-efficacy-and-safety-of-everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-metallic-stents-a-meta-analysis-of-randomized-trials
#12
Ahmed N Mahmoud, Amr F Barakat, Akram Y Elgendy, Erik Schneibel, Amgad Mentias, Ahmed Abuzaid, Islam Y Elgendy
BACKGROUND: Data regarding the long-term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents are limited. This meta-analysis aimed to compare the long-term outcomes with both devices. METHODS AND RESULTS: Randomized trials reporting clinical outcomes beyond 1 year and comparing BVS with everolimus-eluting stents were included. Summary estimates risk ratios (RRs) were constructed. The primary efficacy outcome was target lesion failure, defined as cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization, and the primary safety outcome was definite or probable stent/scaffold thrombosis...
May 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28461150/angina-and-ischemia-at-2-years-with-bioresorbable-vascular-scaffolds-and-metallic-drug-eluting-stents-estrofa-ischemia-bvs-mdes-study
#13
José M de la Torre Hernández, José R Rumoroso, Soledad Ojeda, Salvatore Brugaletta, José D Cascón, Cristina Ruisánchez, Joaquín Sánchez Gila, Jessica Roa, Helena Tizón, Hipólito Gutiérrez, Mariano Larman, Tamara García Camarero, Eduardo Pinar, José F Díaz, Manuel Pan, Miren Morillas Bueno, José M Oyonarte, Luis Ruiz Guerrero, Mireia Ble, Ramón Rubio Patón, Román Arnold, Kattalin Echegaray, Gonzalo de la Morena, Manel Sabate
INTRODUCTION AND OBJECTIVES: Bioresorbable vascular scaffolds (BVS) have the potential to restore vasomotion but the clinical implications are unknown. We sought to evaluate angina and ischemia in the long-term in patients treated with BVS and metallic drug-eluting stents (mDES). METHODS: Multicenter study including patients with 24 ± 6 months of uneventful follow-up, in which stress echocardiography was performed and functional status was assessed by the Seattle Angina Questionnaire (SAQ)...
April 28, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28446750/expandable-mg-based-helical-stent-assessment-using-static-dynamic-and-porcine-ex-vivo-models
#14
Youngmi Koo, Tarannum Tiasha, Vesselin N Shanov, Yeoheung Yun
A bioresorbable metallic helical stent was explored as a new device opportunity (magnesium scaffold), which can be absorbed by the body without leaving a trace and simultaneously allowing restoration of vasoreactivity with the potential for vessel remodeling. In this study, developed Mg-based helical stent was inserted and expanded in vessels with subsequent degradation in various environments including static, dynamic, and porcine ex vivo models. By assessing stent degradation in three different environments, we observed: (1) stress- and flow-induced degradation; (2) a high degradation rate in the dynamic reactor; (3) production of intermediate products (MgO/Mg(OH)2 and Ca/P) during degradation; and (4) intermediate micro-gas pocket formation in the neighboring tissue ex vivo model...
April 26, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28440067/real-life-data-regard%C3%A4-ng-acute-procedural-success-and-1-year-clinical-outcome-of-desolve-bioresorbable-scaffolds
#15
Haci Murat Gunes, Tayyar Gokdeniz, Filiz Kizilirmak Yilmaz, Gultekin Gunhan Demir, Ekrem Guler, Gamze Babur Guler, Oğuz Karaca, Beytullah Cakal, Mehmet Onur Omaygenç, Ersin İbişoğlu, Bilal Boztosun
OBJECTIVES: We aimed to evaluate the peri-procedural success of DESolve bio-resorbable scaffolds (BRSs) and analyzed real-life data about major cardiac events during 1-year follow-up. BACKGROUND: There is little information about real-life data of DESolve BRS which is a novel stent technology offering various advantages over drug eluting stents and commonly used in daily cardiology practice. METHODS: We conducted this single-center and non-randomized cross-sectional study from June 2015 through August 2016 in Medipol University Department of Cardiology and included 117 patients undergoing single or multivessel percutaneous coronary interventions (PCI) with novolimus-eluting BRS devices (152 scaffolds) (Elixir Medical Corporation)...
April 25, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28438304/thirty-day-outcomes-after-unrestricted-implantation-of-bioresorbable-vascular-scaffold-from-the-prospective-rai-registry
#16
Bernardo Cortese, Alfonso Ielasi, Elisabetta Moscarella, Bruno Loi, Giuseppe Tarantini, Francesco Pisano, Alessandro Durante, Giampaolo Pasquetto, Alessandro Colombo, Gabriele Tumminello, Luciano Moretti, Paolo Calabrò, Pietro Mazzarotto, Attilio Varricchio, Maurizio Tespili, Roberto A Latini, Gianfranco Defilippi, Donatella Corrado, Giuseppe Steffenino
The Absorb biovascular scaffold (BVS) is a bioresorbable, everolimus-eluting scaffold whose data on real-world patients with complex lesions are limited. Short-term follow-up from recent studies point to a higher rate of 30-day thrombosis than observed with drug-eluting stents. We aimed to understand the short-term safety and efficacy of BVS. Registro Absorb Italiano (RAI, ClinicalTrials.gov:NCT02298413) is an Italian, prospective, multicenter registry not funded, whose aim is to investigate BVS performance through a 5-year follow-up of all consecutive patients who have undergone successful implantation of ≥1 BVS in different clinical/lesion subsets...
March 29, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28432385/bioresorbable-vascular-scaffolds-in-coronary-chronic-total-occlusions-revascularization-safety-assessment-related-to-struts-coverage-and-apposition-in-6-month-oct-follow-up
#17
Rosa Alba Abellas-Sequeiros, Raymundo Ocaranza-Sanchez, Ramiro Trillo-Nouche, Carlos Gonzalez-Juanatey, Jose Ramon Gonzalez-Juanatey
Beneficial properties of bioresorbable vascular scaffolds (BVS) regarding to vasomotility restoration and no caging of the vessel make them attractive devices in chronic total occlusions (CTO) revascularization. However, more evidence is needed attending to their use in this specific setting. We aim to determine feasibility and safety of BVS use in CTO revascularization attending to struts coverage and apposition, as well as re-stenosis and stent thrombosis (ST) rates. 29 BVS were deployed in 9 CTO lesions revascularization (mean J-CTO score ≥3) with an acute procedural success rate of 100%...
April 21, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28430908/late-thrombotic-events-after-bioresorbable-scaffold-implantation-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#18
Carlos Collet, Taku Asano, Yosuke Miyazaki, Erhan Tenekecioglu, Yuki Katagiri, Yohei Sotomi, Rafael Cavalcante, Robbert J de Winter, Takeshi Kimura, Runlin Gao, Serban Puricel, Stéphane Cook, Davide Capodanno, Yoshinobu Onuma, Patrick W Serruys
Aims: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and Results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI)...
April 18, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28427594/the-bioresorbable-drug-eluting-coronary%C3%A2-stent-the-price-is-right
#19
EDITORIAL
Michael A Kutcher
No abstract text is available yet for this article.
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28427593/economic-outcomes-of-bioresorbable%C3%A2-vascular-scaffolds-versus%C3%A2-everolimus-eluting-stents-in-patients%C3%A2-undergoing-percutaneous-coronary-intervention-1-year-results-from-the-absorb%C3%A2-iii-trial
#20
Suzanne J Baron, Yang Lei, Khaja Chinnakondepalli, Katherine Vilain, Elizabeth A Magnuson, Dean J Kereiakes, Stephen G Ellis, Gregg W Stone, David J Cohen
OBJECTIVES: The purpose of this study was to evaluate the economic impact of the Absorb bioresorbable vascular scaffold compared with the Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention. BACKGROUND: The ABSORB III trial (Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease) demonstrated that the Absorb scaffold was noninferior to the Xience stent with respect to target lesion failure at 1 year. Whether health care costs differ between the Absorb scaffold and the Xience stent is unknown...
April 24, 2017: JACC. Cardiovascular Interventions
keyword
keyword
116611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"